Hizentra is an Ig* therapy that provides proven CIDP relapse prevention with the convenience of self-administration, so you can focus on everyday living
Other Ig treatments for chronic inflammatory demyelinating polyneuropathy (CIDP) require IV infusions into your veins. With Hizentra, an IV is not involved: instead you can self-infuse just under the skin, not into a vein, after receiving training from your doctor.
Hizentra gives you proven control with a smaller volume per dose than IVIg, plus convenient dosing to fit your lifestyle. In clinical trials, Hizentra had fewer systemic side effects per infusion (like headache and nausea) than IVIg. The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting.
Hizentra is a prescription medicine used to treat CIDP in adults.
These programs feature a presentation from a trained nurse and stories from a patient just like you.
Watch a video below to learn more.
†Voice2Voice advocates are not healthcare professionals or medical experts. For medical questions, please contact your physician. Voice2Voice advocates are compensated by CSL Behring LLC. for their time and/or expenses.
With Premier Start, you can receive:
The Hizentra Co-Pay Relief program helps eligible people afford their therapy by assisting with monthly out-of-pocket expenses for Hizentra (up to $5,000 for each year, with no monthly cap). Most patients with commercial insurance pay $0 out-of-pocket.See if you are eligible
CSL Behring Assurance is a program that can help eligible patients continue to receive treatment even if they experience a lapse in third-party private health insurance.Learn how it works